Biogen Idec Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
342.68 -0.36   -0.10%715,575739.3K
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. As of 03:59 PM ET 9/2/2014

Latest News Headlines for Biogen Idec Inc

Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--September 02, 2014-- Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley Global Healthcare Conference 2014. The webcast will be live on Monday, September 8, 2014 at 2:00p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.

Acquisitions, Appointments, Patent Grant, Technical Updates, and Awareness Campaign - Research Reports on Covidien, Biogen Idec, Achillion, Intercept and Mylan

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, August 28, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding Covidien plc (NYSE: COV), Biogen Idec Inc. (NASDAQ: BIIB), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6032-100free.

Biogen Idec in Panel at the Citi 9(th) Annual Biotech Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 26, 2014-- Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will participate in a panel at the Citi 9(th) Annual Biotech Conference. The webcast will be live on Thursday, September 4, 2014 at 10:00a.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company's products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

http://www.biogenidec.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open345.47
Previous Close343.04
Day High347.7892
Day Low340.60
52 Week High3/19/2014 | 358.89
52 Week Low9/3/2013 | 213.05
% Off 52 Week High-4.52%
% Off 52 Week Low60.84%
Beta (5 Yr)1.2
Volatility Avg8/29/2014 | 36.93
10-Day Avg. Volume739,343
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2014 | 9.00
P/E Ratio6/30/2014 | 38.1
Market CapLarge Cap | 80.9B
Shares Outstanding236.15M
Float235.9M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short3.31M
Short Ratio2.8
Short % of Float1.40%
As of 8/15/2014

Peers Information HelpBIIB Biogen Idec Inc vs. Peers

Peers 
BIIB
Biogen Idec Inc
22.70%
Johnson & Johnson
13.25%
Pfizer Inc.
-4.05%
Merck & Co., Inc.
20.10%
AbbVie Inc
4.68%
BIIB
Biogen Idec Inc
0.00%
Johnson & Johnson
2.70%
Pfizer Inc.
3.54%
Merck & Co., Inc.
2.93%
AbbVie Inc
3.04%
BIIB
Biogen Idec Inc
-0.10%
Johnson & Johnson
-0.36%
Pfizer Inc.
-0.44%
Merck & Co., Inc.
-0.53%
AbbVie Inc
-0.38%
Compare these stocks